Roche’s Giredestrant sets new benchmark in early breast cancer treatment
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
Both companies will jointly execute development and scale-up of multiple strategic APIs, including late-stage NCE-1 opportunities
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
AGA affects up to 80 per cent of men across their lifetime and remains one of the most common and most psychologically challenging forms of hair loss
Both companies will promote, market and distribute Sodium Zirconium Cyclosilicate in India under different brand names
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD
OncoMate MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
Subscribe To Our Newsletter & Stay Updated